Leading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the SpecialtyHINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, being held from July 16-20, in Strasbourg, France. The Company applauds the SRS for recognizing the growing need to spotlight this fi ...

RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The repurchase was completed as part of the Company’s capital formation strategy and reflects its continued confidence in its product development of a long-te ...

Core Insights - SeaStar Medical Holding Corporation has introduced QUELIMMUNE therapy at Texas Children's Hospital, which is a potential life-saving treatment for pediatric patients with acute kidney injury (AKI) due to sepsis [1][2] - The QUELIMMUNE therapy has shown a 77% survival rate compared to standard care, indicating a 50% reduction in loss of life in this patient population [1][4] - The therapy is designed to neutralize over-active immune cells and mitigate hyperinflammation, which is critical in treating AKI [2][8] Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure [9] - The QUELIMMUNE therapy is the only FDA-approved product for life-threatening AKI in critically ill pediatric patients [9] - The company has received Breakthrough Device Designation for six therapeutic indications, facilitating a faster approval process [9] Clinical Data and Trials - Clinical data published in Kidney Medicine supports the efficacy of QUELIMMUNE, showing no dialysis required for survivors at Day 60 post-ICU discharge [1][6] - SeaStar Medical is conducting the NEUTRALIZE-AKI pivotal trial to evaluate the safety and efficacy of SCD therapy in adults with AKI [3][7] - The primary endpoint of the NEUTRALIZE-AKI trial includes a composite of 90-day mortality or dialysis dependency [7] Market Impact - The introduction of QUELIMMUNE addresses a significant unmet need for organ-sparing therapies in pediatric patients [2] - The therapy aims to reduce healthcare costs associated with prolonged ICU stays and reliance on dialysis [3] - SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its contributions to pediatric AKI treatment [6]

NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) have each recommended that stockholders vote “FOR” the previously announced acquisition of the Company by RadNet, Inc. (“RadNet”) at the Company’s upcoming Special Meeting of Stockholder ...

Core Insights - Xtant Medical Holdings, Inc. has announced the sale of certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC for a total consideration of approximately $19.2 million [1][2] - The transaction is expected to close in the third quarter of 2025 and aims to enhance Xtant's focus on its core business while improving its balance sheet and liquidity [2][3] Financial Details - The proceeds from the transaction consist of $11 million in cash at closing and $8.2 million in short-term seller financing [2][4] - Xtant plans to use the proceeds to reduce long-term debt and improve cash liquidity [2] Strategic Focus - The transaction allows Xtant to concentrate on the development of higher-margin orthobiologics, thereby streamlining operations [3] - Companion Spine, backed by Viscogliosi Brothers, is expected to effectively manage the transitioned products and drive their growth [3] Operational Transition - Certain members of Xtant's U.S. and international commercial organizations will transition to Companion Spine to continue supporting the products [2] - Companion Spine aims to enhance its product solutions portfolio and strengthen its presence in the U.S. market [3][8] Closing Conditions - The transaction is subject to Companion Spine obtaining financing and other customary closing conditions [3]

Company Overview - UFP Technologies, Inc. is a contract development and manufacturing organization (CDMO) specializing in single-use, polymer-based medical devices and components [2] - The company partners with leading medical device companies to design and manufacture new devices, focusing on improving patient outcomes while reducing costs [2] - UFP Technologies operates in high-barrier, regulated markets such as robotic-assisted surgery, safe patient handling, infection prevention, interventional devices, orthopedics, and wound care [2] Recent Developments - UFP Technologies announced that its President Mitchell Rock and Sr. Vice President & CFO Ron Lataille will present and host one-on-one meetings at the CJS Securities 25th Annual Summer Conference on July 10, 2025 [1]

Market Opportunity & Growth - The company is a global leader in therapeutic ultrasound for cancer and benign diseases, with a strong growth opportunity in urology and prostate cancer[4,6] - Prostate cancer is the most common cancer among men in the US, with 33 million American men living with it in 2025, and 313780 new cases diagnosed[14,15] - Globally, there are approximately 15 million new prostate cancer cases per year as of 2022, with Europe accounting for 473011 cases, Asia for 386424 cases, and North America for 255782 cases[19,20] - The annual procedure opportunity for Focal One HIFU in prostate cancer is estimated at 470000 globally, including 165000 in Europe, 130000 in Asia, and 100000 in North America[25] Clinical Evidence & Technology - Over 1000 peer-reviewed publications support HIFU in the treatment of prostate cancer[36] - A comparative study (HIFI) showed comparable cancer control with HIFU (90% STFS) versus radical prostatectomy (86% STFS), with superior functional outcomes for HIFU[41,45] - A randomized controlled trial (FARP) demonstrated equivalent oncologic control at 3 years (935% TFF for Focal Ablation vs 915% for Radical Prostatectomy) and superior functional outcomes after focal ablation[54] - The company's Focal One system has 11 systems in the NY/NJ MSA at the end of 2024 and 67 systems in the US at the end of Q1 2025[104,107] Reimbursement & Expansion - Medicare reimbursement for HIFU is $9247 in 2025, a 54% increase, and physician payment is $951[70,73] - The company is targeting large incidence cancer and benign conditions, including 15 million prostate cancer cases, 113 million BPH cases, and 205 million rectal endometriosis cases[89]

A European business group in China has criticized Beijing’s retaliatory measures targeting medical device makers from the European Union, saying the move worsens ties between the two economic powers. https://t.co/lEgyzPHXyC ...

Company Performance - CRISPR Therapeutics AG (CRSP) ended the recent trading session at $51.19, showing a -1.88% change from the previous day's closing price, which lagged behind the S&P 500's daily loss of 0.79% [1] - The stock has risen by 24.63% in the past month, outperforming the Medical sector's gain of 1.49% and the S&P 500's gain of 5.22% [1] Financial Forecast - The company is forecasted to report an EPS of -$1.54, reflecting a 3.36% decrease from the same quarter of the previous year [2] - Quarterly revenue is expected to be $5.89 million, representing a significant increase of 1032.88% from the year-ago period [2] Full-Year Estimates - Full-year Zacks Consensus Estimates predict earnings of -$5.54 per share and revenue of $39.95 million, indicating year-over-year changes of -27.65% and +7.06%, respectively [3] - Recent changes to analyst estimates for CRISPR Therapeutics AG can indicate short-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Performance - The Zacks Rank system, which includes estimate changes, has a proven track record of outperformance, with 1 stocks returning an average of +25% annually since 1988 [5] - CRISPR Therapeutics AG currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 77, placing it within the top 32% of over 250 industries [6]

Group 1 - BD has appointed Bilal Muhsin as executive vice president and president of the future Connected Care segment, effective July 2, 2025, as part of its New BD strategy [1][2] - Under Muhsin's leadership, BD Connected Care will focus on leveraging advanced analytics and AI solutions to enhance patient care efficiency and effectiveness, while exploring growth opportunities in areas like connected medication management and smart monitoring solutions [2][3] - Muhsin brings 25 years of experience from Masimo, where he held various leadership roles, including chief operating officer, and has a strong background in medical engineering and software development, holding over 50 patents [3][4] Group 2 - BD is recognized as one of the largest global medical technology companies, dedicated to improving medical discovery, diagnostics, and care delivery through innovative technology and solutions [5] - The company employs over 70,000 individuals and collaborates with global organizations to tackle significant health challenges, aiming to enhance outcomes, reduce costs, and improve healthcare access [5]